Особенности регуляции апоптоза при опухолевых, вирусных и аутоиммунных заболеваниях
Диссертация
Среди заболеваний, связанных с усилением апоптоза, особое внимание следует уделить вирусным и аутоиммунным заболеваниям. В последние годы широким кругом специалистов ведется интенсивное изучение проблемы хронических вирусных гепатитов В и С (ХВГ В и С), которая приобретает социальную значимость ввиду широкого распространения этих заболеваний, роста заболеваемости, особенно среди лиц молодого… Читать ещё >
Список литературы
- Аббасова С.Г., Липкин В. М., Трапезников H.H., Кушлинский Н. Е. Система Fas-FasL в норме и при патологии // Вопросы биологической, медицинской и фармацевтической химии. 1999.- № 3.- С.3−17
- Аксель Е.М., Казубская Т. П., Белев Н. Ф. и др. Генетика рака желудочно-кишечного тракта. 2001. -№ 4.~ Т. З.-С. 141−145
- Барышников. А.Ю., Шишкин Ю. В. Иммунологические проблемы апоптоза //Москва.-2002. С. 18−37.
- Баснакьян А.Г., Басков A.B., Соколов H.H., Борщенко И. А. Апоптоз при травматическом повреждении спинного мозга: перспективы фармакологической коррекции// Вопросы медицинской химии.- 2000.- № 5.-С.
- Белецкий И.П., Сорокина О. В., Никонова Л. В. Генная терапия на основе системы Раз-антиген-Раз-лиганд // Вопросы биологической медицинской и фармацевтической химии 1999. — № 4. — С.40−49
- Воробьев Г. И., Одарюк Т. С., Шелыгин Ю. А. Диагностика и лечение рака толстой кишки // Русский медицинский журнал. 1998. -том 6. -№ 19. -с. 1244−1256
- Гарькавцева Р.Ф., Давыдов М. И., Ушакова Т. И. и др. Злокачественные новообразования желудочно-кишечного тракта: основные статистические показатели и тенденции // Современная онкология. 2001. — № 4. — Т. 3. — С. 151 153
- Жданов Р.И. Генная терапия: надежды и реалии // Вопросы биологической, медицинской и фармацевтической химии. 1999. — № 4. — С.3−6.
- Змызгова A.B., Москалева Е. Ю., Максимов С. Л. и др. Структура ДНК лейкоцитов периферической крови и показатели клеточного иммунитета больных вирусным гепатитом В // Вопросы биологической, медицинской и фармацевтической химии. -1999, № 2, с. 16−19
- Лунькова Л.К., Макарова О. В., Каниболоцкий A.A., Миткова C.B. Морфология органов иммунной системы при наркомании // Архив патологии.-2002.-№ 4. -С.21−25
- Лушников Е.Ф., Абросимов А. Ю. Гибель клетки (апоптоз). М.: Медицина, 2001. -192 с.
- Молекулярная клиническая диагностика. Методы: Пер. с англ./ Под ред. С Херрингтона, Дж. Макги. М.: Мир, 1999. — 558 с.
- Нестерова М.В., Чо-Чанг Ю.С., Северин Е. С. Роль антисмысловых олигонуклеотидов в регуляции клеточных процессов. // Вопросы биологической, медицинской и фармацевтической химии. 1998. — № 4. — С.3−14.
- Петрова У. Н., Радыгина Т. В., Лыскина Г. А., Продеус А. П. Современные аспекты этиопатогенеза системной красной волчанки // вопр. Гематол. И иммунопатол. В педиатр. 2002. — Т. 1, № 1. -С.92−94.
- Практическая химия белка: Пер. с англ./ Под ред. А. Дарбле. М.: Мир, 1989. — 623 с.
- Программированная клеточная гибель под ред. Новикова B.C., Санкт-Петербург.-1996.
- Северин С.Е. Биохимия и медицина новые подходы и достижения. — М.: Русский врач, 1998. — 96с.
- Сладкова Л. В., Москалева Е. Ю., Посыпанова Г. А. и др. Устойчивость В-клеточных линий человека с разным уровнем экспрессии Вс1−2 к противоопухолевым препаратам / / Вопр. биол., мед. и фарм. химии. — 2000. — № 3, —С. 25−29.
- Смирнов А.Б. Заболеваемость раком желудка. http://www.sci.aha.ru/ATL/ra531.htm. -1998
- Федоров Н.А., Суханов Ю. С., Асади Мобархан А.Х., Артемьев М. И. Полимеразная цепная реакция (ПЦР). Методическое пособие для начинающих/Принципы и практические рекомендации для ее постановки с целью детекции микроорганизмов. — 1996.- 33 с.
- Чемерис А.В., Ахунов Э. Д., Вахитов В. А. Секвенирование ДНК. М.: Наука, 1999. -429 с.
- Ackermann Е. J., Taylor J. К., Narayana R. et al. The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides // The journal of biological chemistry. 1999. — Vol. 274. — N. 16. — P. 11 245−11 252
- Adrain C., Creagh E. M., Martin S. J. Apoptosis-associated release of Smac/DIABLO from mitochondria requires active caspases and is blocked by Bcl-2 // The EMBO journal.- 2001. Vol. 20. — N. 23. — P. 6627−6636
- Akshay KV., Orlinick J R. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations// J Clin Invest. 1999. — Vol. 103, №. 3. — P. 355−363.
- A1 Maini MH., Mountz JD., AlMohri HA., et al. Serum levels of soluble Fas correlate with induces of organ damage in systemic lupus erythematosus// Lupus. 2000. — Vol. 9. -P.132−139.
- Almawi W.Y., Melemedjian O. K., and Abou Jaoude M. M. On the link between Bcl-2 family proteins and glucocorticoid-induced apoptosis // J. Leukoc. Biol. 2004. -V. 76. -P. 7−14
- Ambar B.B., Frei K., Malipiero U. et al. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand //Hum Gene Ther.-1999.- V. 10, — P. 1641−1648.
- Andrade F., Casciola-Rosen L., Rosen A. apoptosis in systemic lupus erythematosus. Clinical implications// Rheum Dis Clin North Am. 2000. — Vol.26. — P.215−27.
- Antonsson B. Bax and other pro-apoptotic Bcl-2 family «killer-proteins» and their victim the mitochondrion // Cell Tissue Res. 2001. — Vol. 306. — N. 3. — P. 347−361
- Antonsson B., Montessuit S., Sanchez B. et al. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells // The journal of biological chemistry.-2001.-Vol. 276.-N. 15-P. 11 615−11 623
- Aoki K., Akyurek L.M., San H., et al. Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy// Mol Ther. -2000.-V.l.-P. 555−565
- Arafat W.O., Gomez-Navarro J., Xiang J. et al. An adenovirus encoding proapoptotic Bax induces apoptosis and enhances the radiation effect in human ovarian cancer// Molecular Therapy.-2000.-V.1.-P. 545−554
- Aral H., Gordon D., Nabel E. G., Nabel G. J. Gene transfer of Fas ligand induces tumor regression in vivo // Proc. nat. Acad. Sci. USA. 1997. — Vol. 94, N 25. — P. 1 386 213 867.
- Arends M. J., Wyllie A. H. Apoptosis. Mechanism and role in pathology // Inlern. Rev. Exp. Pathol. -1991. Vol.32. — P.223−254.
- Aschoff A. P., Ott U., Funfstuck R. et al. Colocalisation of Bax and Bcl-2 in small intestine and kidney biobsies with different degrees of DNA fragmentation // Cell Tissue Res. 1999.-Vol. 296.-P. 351−357
- Ashkenazi A., Pai, R.C., Fong S. et al. Safety and antitumor activity of recombinant soluble Apo2 ligand// Clinical Investigation. 1999.- V. 104. — P. 155−162
- Ayhan A., Yasui W., Yokozaki H. et al. Loss of heterozygosity at the Bcl-2 gene locus and expression of Bcl-2 in human gastric and colorectal carcinomas // Jpn. J. Cancer research. 1994. — Vol. 85. — N. 6. — P. 584−591
- Bardelli A. HGF receptor associates with the anti-apoptotic protein Bag-1 and prevents cell death // The EMBO journal. 1996. — Vol. 15. — P. 6205−6212
- Basanez G., Nechushtan A., Drozhinin O. et al. Bax, but not Bcl-XL, decreases the lifetime of planar phospholipid bilayer membranes at subnanomolar concentrations // Proc. Natl. Acad. Sci. USA. 1999. — Vol. 96. — N. 10. — P. 5492−5497
- Basanez G., Zhang J., Chau B. N. et al. Pro-apoptotic cleavage products of Bcl-XL form cytochrome c-conducting pores in pure lipid membranes // The journal of biological chemistry. 2001. — Vol. 276. — P. 31 083−31 091
- Batteux F., Tourneur L, Trebeden H. et al. Gene therapy of experimental autoimmune thyroiditis by in vivo administration of plasmid DNA coding for Fas ligand // J. Immunol. — 1999. — Vol. 162, N 1. P. 603−608.
- Baumann H., Gearing D., Ziegler S. F. Signaling by the cytoplasmic domain of hematopoietin receptors involves two distinguishable mechanisms in hepatic cells // J. Biol. Chem. — 1994, — Vol. 269, N 23. P. 16 297−16 304.
- Bellgrau D., Gold D., Selawry H. et al. A role for CD95 ligand in preventing graft rejection // Nature. — 1995. — Vol. 377, N 6550. P. 630−632.
- Bennett M.W., O’Connell J., Houston A. et al. Fas ligand upregulation is an early event in colonic carcinogenesis // J. Clin. Pathol. 2001. — Vol. 54. — N. 8. — P. 598−604
- Bennett M.R. Apoptosis in the cardiovascular system// Heart.- 2002.-V. 87.- № 5.-P. 480−487
- Bennett M.W., O’connell J., O’sullivan G.C. et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer // Gut. 1999.-Vol. 44.-N. 2.-P. 156−162
- Berke G. Killing mechanisms of cytotoxic lymphocytes. Curr Opin Hematol 1997−4:32−40
- Berman M. L, Silhavy T. J., Enquist L. W. Experiments with gene fusions. — New York, 1984.
- Biswas S. K., Huang J., Persaud S., and Basu A. Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells //Mol. Cancer Ther.-2004.-V.3.-P. 327−334
- Bodmer J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8 //Nature Cell Biology. 2000. — V. 2.- P. 241−243
- Boerrigter ME., Mullaart ET., Van der Schans G. P., Vijg I. Quiescent human peripheral blood lymphocytes do not contain a sizable amount of preexistent DNA single-strand breaks // Exp. Cell Res. 1989. — Vol. 180. — P. 569 — 573.
- Boerrigter M. E. T. I., Mullaart E., Van der Schans G. P., Vijg I. Illusory DNA breaks in quiescent lymphocytes? // Cancer Res. 1990. — Vol. 188. — P. 1 -4.
- Bonavida B., Ng C.P., Jazirehi A., Schiller G., and Mizutani Y. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics //International Journal of Oncology.-1999.-V. 15. P. 793−802
- Bortner C D et al. The role of DNA fragmentation in apoptosis. Trends in cell biology 1995−5:21−26.
- Bosari S., Moneghini L., Graziani D. et al. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas // Hum. Pathol. 1995. — Vol. 26. — N. 5. — P. 534−540
- Brada M. Bcl-2 gene: current relevance to clinical oncology // Eur. J. Cancer. 1992. -Vol. 28. — P. 270−272.
- Brady H.J.M., Gil-Gomez G. Molecules in focus Bax. The pro-apoptotic Bcl-2 family member, Bax // The international journal of boichemistry and cell biology. 1998. — Vol. 30. — P. 6407−650
- Branet F., Brousset P., Krajevski S. Expression of the cell death inducing gene Bax in carcinomas developed from the follicular cells of the thyroid gland // Journal of clinical endocrinology and metabolism. 1996. — Vol. 81. -N. 7. — P. P2726-P2730
- Bresalier R. S. Colorectal cancer // Cancer and metastases reviews.-2004.-V.23.-P.7−10
- Bunnel B.A., Morgan R.A. Gene therapy for infectious diseases // Clin. Microb. Rev. -1998. V. l 1. — N.l. — P.42−56
- Butler L.M., Hewett P.J., Butler W.J. et al. Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement // Br. J. Cancer. 1998. -Vol. 77.-N. 9.-P. 1454−1459
- CandeC., Vahsen N., Garrido C., Kroemer G. Apoptosis-inducing factor (AIF) — caspase independent after all //Cell death. 2004. — V. l 1 — P.591−595
- Chandra D., Liu J.-W., Tang D. G. Early Mitochondrial activation and cytochrome c up-regulation during apoptosis // The journal of biological chemistry. 2002. — Vol. 277. -N. 52.-P. 50 842−50 854
- Chang B. S., Minn A. J., Muchmore S.W. et al. Identification of a novel regulatory domain in Bcl-XL and Bcl-2 // The EMBO journal. 1997. — Vol. 16. — N. 5. — P. 968 977
- Chao D. T., Korsmeyer S. J. Bcl-2 family: regulators of cell death // Annu. Rev. Immunol. 1998. — Vol. 16. — P. 395−419
- Charalambous G. K., Gomatos I. P., Konstadoulakis M. M. et al. Protein expression of Bax, Bcl-2, and p53 in patients with non-Hodgkin's gastric lymphoma: prognostic significance // World j. Surg. 2000. — Vol. 24. — P. 608−614
- Chen Y., Wilson J. M. Fas ligand — a double-edged sword // Nature Biotechnol. 1998. -Vol. 16, N 11.-P. 1011−1012.
- Cheng J., Zhou T. Protection from Fas-mediated apoptosis by a soluble form of Fas molecule // science. 1994. — Vol. 263. — P. 1759−1762.
- Chinnaiyan A.M., O’Rourke K., Lane B.R., Dixit V.M. Interaction of Ced-4 with Ced-3 and Ced-9: a molecular frame for cell death // Science. 1997. — Vol. 275. — P. 1122−1126
- Chizari FV, Ferrari C. Hepatitis B virus immunopathogenesis//Annu Rev Immunol 1995, 13.29−60
- Ciardiello F. and Tortora G. Inhibition of bcl-2 as cancer therapy // Ann. One. 2002.-V.13(4). — P. 501 -502
- Cohen J. Apoptosis: the physiologic pathway of cell death // Hosp. Pract. 1993. -Vol.28.-N12.- P.35−43.
- Crovatto M., Pozatto G., Zorat F. et al. Peripheral blood neutrophils from hepatitis C virus-infected patients are replication sites of the virus//Haematologica 85 (4), 356−361 (2000)
- Cuconati A., White E. Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection // Genes Dev. 2002. — Vol. 16. — N. 19. — P. 2465−2478.
- Curiel D.T., Douglas J.T. Adenoviral Vectors for Gene Therapy. Academic Press. 2002. — C.677
- Dutton G. Debating Gene Therapy’s Future // Genetic Engineering News. 2000. -V.20. — № 1.
- Eissa S., Seada L.S. Quantitation of Bcl-2 protein in bladder cancer tissue by enzyme immunoassay: comparison with Western blot and immenohistochemistry // Clinical chemistry. 1998. — Vol. 44. -N. 7. — P. 1423−1429
- Eskes R., Antonsson B., Osen-Sand A. et al. Bax-induced cytochrome c release from mitochondria is independent of the permeability transition pore but highly dependent on Mg2+ ions // The journal of cell biology. 1998. — Vol. 143. — P. 217−224
- Eskes R., Desagher S., Antonsson B. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane // Molecular and cellular biology. 2000. -Vol. 20. -N. 3. — P. 929−935
- Fadok V.A., Bratton D.L., Henson P.M. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences// J. Clin. Invest.- 2001.-V. 108.-№ 7.-P.957−962.
- Farid P., Gomb S.Z., Peter I. et al. Bcl-2, p53 and Bax in thyroid tumors and their relation to apoptosis // Neoplasma. 2001. — Vol. 48. -N. 4. — P. 299−301
- Ferrante A., Thong Y.H. A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique // J. Immunol. Methods. 1978. — Vol. 24. — P. 389−393
- Ferraro E., Corvaro M., Cecconi F. Physiological and pathological roles of Apafl and apoptosome// J.Cell.Mol.Med.- 2003, — V.7.-P.21−34
- Feudis P., Vignati S., Rossi C., et al., Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis.//Neoplasia. 2000. — Vol.2. — P.202−207.
- Finucane D. M., Bossy-Wetzel E., Waterhouse N. J. et al. Bax induced caspase activation and apoptosis via cytochrome c release from mitochondria is inhibitable by Bcl-XL // The journal of biological chemistry. 1999. — Vol. 274. — N. 4. — P. 2225−2233
- Franziska Oberhammer et al. Apoptotic death in epithelial cells: cleavage of DNA to 300 and/or 50kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO 1993- 12: 3679−3684.
- Friess H., Lu Z., Graber H. U. et al. Bax, but not Bcl-2, influences the prognosis of human pancreatic cancer // Gut. 1998. — Vol. 43. — P. 414−421
- Galle PR, Hoffmann WJ, Walsczac H et al. Involvement of the CD 95 (APO-l/Fas)receptor and ligand in liver damage. J Exp Med 1995- 182: 1223−30
- Gaumann A., Tews D.S., Mayer E. et al. Expression of apoptosis-related proteins, p53, and DNA fragmentation in sarcomas of the pulmonary artery // Cancer. 2001. — Vol. 92.-N. 5.-P. 1237−1244
- Gene Medicine Therapy Clinical Trials// www. wiley .co.uk
- Gewirtz M. Oligonucleotide Therapeutics: A Step Forward // J. Clin. Oncol. 2000.-V. 18(9).-P. 1809- 1811
- Gil J., Yamamoto H., Zapata J. M. et al. Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers // Cancer research. 1999. -Vol. 59.-P. 2034−2037
- Glaser V. Antisense Drug Hope to Enter the Mainstream // Genetic Ingineering News. -2003.- Vol.23.- No.18.-P.l-14
- Golstein P. Controlling cell death // Sceince 1997, v.275, p.1081−1082.
- Gong B., Chen Q., Endlich B. et al. Ionizing radiation induced Bax mediated cell death is dependent on activation of cysteine and serine proteases // Cell Growth & Differentiation. -1999.-Vol. 10.-P. 491−502
- Grady W.M. Genomic instability and colon cancer// Cancer and metastases reviews.-2004.-V.23.-P. 11−27
- Green D. R., Ware C. F. Fas-ligand: privilege and peril // Proc. nat. Acad. Sci. USA. 1997. — Vol. 94, N 12. — P. 59 865 990
- Griffith T.S., Brunner T., Fletcher S.M., Green D.R. and Ferguson T.A. Fas ligand-induced apoptosis as a mechanism of immune privilege// Science.- 1995.-V. 270.-P. 1189−1192
- Groeger A.M., Esposito V., Cassandro R. et al. A model of BAX gene delivery to human lung cancer// Anticancer Res. 2001.- V.21(5).- P.3627−3630
- Gross A., Jockel J., Wei M.C., Kosmeyer S.J. Enforced dimerization of Bax results in its translocation, mitochondrial disfunction and apoptosis. // EMBOj. 1998. -Vol.17. — P.3878 — 3885.
- Gross A., McDonnell J. M., Korsmeyer S. J. Bcl-2 family members and the mitochondria in apoptosis // Genes Dev. 1999. — Vol. 13. — N. 15. — P. 1899−1911
- Gu J., Zhang L., Huang X., Lin T. et al. A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo //Oncogene. -2002.-V. 18−21(31).-P.4757−4764
- Guo B., Godzik A., Reed Y.R. Bcl-G, a novel pro-apoptotic member of the Bcl-2 family // The journal of biological chemistry. 2001. — Vol. 276. — N. 4. — P. 2780−2785
- Guo Bin, Cao Sh., Toth K. et al. Overexpression of Bax enchances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma.// Clin Cancer Res. 2004 — Vol.6. — P.718−724.
- Guo Y., Srinivasula S. M., Druilhe A. et al. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria// The journal of biological chemistry. 2002. — Vol. 277. — P. 13 430−13 437
- Hague A., Moorghen M., Hicks D. et al. Bcl-2 expression in human colorectal adenomas and carcinomas // Oncogene. — 1994. Vol. 9. — P. 3367−3370.
- Hall W.W., Lin C.R., Shneewind O. Detected HTLV1 in blood and cutaneous lesions of patients with mycosis fungoides // Science. 1991. — V.253. — P.317−320
- Hardwick J.M. Virus-induced apoptosis // Adv. Pharmacol. -1997, v.41, p.295−336.
- Harima Y., Harima K., Shikata N. et al. Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer // J. Cancer research. Clin. Oncol. 1998. — Vol. 124.-P. 503−510
- Harris M. H., Heiden M. G. V., Kron S. J. et al. Role of oxidative phosphorylation in Bax toxicity // Molecular and cellular biology. 2000. — Vol. 20. — N. 10. — P. 35 903 596
- Haunstetter A., Izumo S. Apoptosis: basic mechanisms and implications for cardiovascular disease// Circ. Res.- 1998-V. 82.- № 1 l.-P.l 111−1129
- Hay S., Kannourakis G. A time to kill: viral manipulation of the cell death program// J. Gen. Virol.- 2002.-V. 83.-P. 1547−1564
- Hayashi, N., E. Mita. Fas system and apoptosis in viral hepatitis. J. Gastroenterol. Hepatol. 12: S223-S226, 1997
- Hedlund T.E., Meech S.J., Srikanth S., Kraft A.S., Miller G.J., Schaack J.B. and Duke R.C. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells // Cell Death Differ.- 1999.-V. 6. P. 175−182
- Heiden M. G. V., Chandel N. S., Li X. X. et al. Outer mitochondrial membrane permeability can regulate coupled respiration and cell survival // Proc. Natl. Acad. Sci. USA. 2000. — Vol. 97. — N. 9. — P. 4666−4671
- Hengarten O.M. The Biochemistry of apoptosis // Nature. 2000. — Vol.407. -P.770−775.
- Hersh E. M., Stopeck A. T. Advances in the biological therapy and gene therapy of malignant disease//Clin. Cancer Res. —1997. Vol. 12, Pt 2. — P. 2623−2639.
- Hiramatsu N, Hayashi N, Katayama K et al. Immunohistochemical detection of Fas antigen in liver tissue of patient with chronic hepatitis C. //Hepatology. 1994.- V. 19.-P.1354−1359
- Hirotani M., Zhang Y., Fujita N. et al. NH2-terminal BH4 domain of Bcl-2 is functional for heterodimerization with Bax and inhibition of apoptosis // The journal of biological chemistry. 1999. — Vol. 274. — N. 29. — P. 20 415−20 420
- Ho V., Baadsgaard O., Lee P.Y.P., Genotipic analysis of T-cell clones arrived from cutaneous T-cell lymphoma lesions demonstrates selective growth of tumor infiltrating T-lymphocytes // J.Invest.Derm. 1990. — V.95. — P.4−8
- Hockenbery D. Defining apoptosis. Review // Amer. J. Pethol. 1995. — Vol.146. — P.16−19.
- Hoetelmans R.W.M., Slooten H-J, Keijzer R. et al. Bcl-2 and Bax proteins are present in interphase nuclei of mammalian cells. //Cell death and Different. 2000. -Vol.7.-P.384−392.
- Holler N., Tardivel A., Kovacsovics-Bankowski M. et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex // Molecular and Cellular Biology. 2003. — Vol. 23. — N. 4. — P. 1428−1440
- Honda M, Kaneko S, Shimazaki T. et al. Hepatitis C virus core protein induces apoptosis and impairs cell-cycle regulation in stably transformed Chinese hamster ovary cells// Hepatology 2000, 31(6), 1351−1359,
- Honda T., Kagawa S., Spurgers K.B. et al. A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity// Cancer Biol. Ther. 2002.- V. I (2).-P. 163−167
- Hsu Y.-T., Youle R. J. Nonionic detergents induce dimerization among members of the Bcl-2 family // The journal of biological chemistry. 1997. — Vol. 272. — N. 21. -P. 13 829−13 834
- Huang D.C.S., O’Reilly L. A., Strasser A. et al. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry // The EMBO journal.- 1997.-Vol. 16.-N. 15.-P. 4628−4638
- Huang D.C.S., Hahne M., Schroeter M. et al. Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-XL // Proc. Natl. Acad. Sci. USA. 1999. — Vol. 96. — P. 14 871−14 876
- Huang X., Lin T., Gu J. et al. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft //Gene Ther. 2002.- V.9(20).-P.1379−1386.
- Huh W.K., Gomez-Navarro J., Arafat W.O., Xiang J., Mahasreshti P.J., Alvarez R.D. Bax-induced apoptosis as a novel gene therapy approach for carcinoma of the cervix//J. Gynecol Oncol. 2001V.83(2).-P.370−377
- Ilyas M., Hao X.P., Wilkinson K. et al. Loss of Bcl-2 expression correlates with tumour recurrence in colorectal cancer // Gut. 1998. — Vol. 43. — N. 3. — P. 383−387
- Inohara N., Ekhterae D., Garcia I. et al. Mtd a novel Bcl-2 family member activates apoptosis in the absence of heterodimerization with Bcl-2 and Bcl-XL // The journal of biological chemistry. — 1998. — Vol. 273. -N. 15. — P. 8705−8710
- Ionov Y., Yamamoto H., Krajewski S. et al. Mutational inactivation of the proapoptotic gene Bax confers selective advantage during tumor clonal evolution // Proc. Natl. Acad. Sci. USA. 2000. — Vol. 97. -N. 20. — P. 10 872−10 877
- Jansson A., Sun X.F. Bax expression decreases significantly from primary tumor to metastasis in colorectal cancer // J. Clin. Oncol. 2002. — Vol. 20. — N. 3. — p. 811−816
- Jeremias, I. and Debatin, K.M. TRAIL induces apoptosis and activation of NF kappa B // European Cytokine Network. 1998. — V. 9. -P. 687−688.
- Jeremy McNally et al. Fas ligand expression and function in systemic lupus erythematosus. J. Immunol. 1997- 159: 4628−4636.
- Jerrold S., Koh LS. The role of apoptosis in autoimmunity: Immunogen, antigen, and accelerant// Seminars in Nephrology. 1999. -Vol.19. -P.34−47.
- Johnson A. L. Editorial: Mcl-1 just another antiapoptotic Bcl-2 homolog? // Endocrinology. — 1999. — Vol. 140. — N. 12. — P. 5465−5468
- Joyner A.L. Gene Targeting. Oxford. 2003. — C.293
- Ju S T. et al. Fas (CD95)/FasL interactions required for programmed cell death after activation. Nature 1995- 373: 444
- Kagawa S., Pearson S.A., Ji L. et al. A binariy adenoviral vector for expressing high levels on the proapoptotic gene bax.// Gene Ther. 2000. — Vol.7. — P.75−79.
- Kagawa Sh., Gu J., Swisher S., et al. Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines. // Cancer Res. 2000. -Vol.60. -P.l 157−1161.
- Kaklamanis L., Savage A., Whitehouse R. et al. Bcl-2 protein expression: association with p53 and prognosis in colorectal cancer // Br. J. Cancer. 1998. — Vol. 77.-N. 11.-P. 1864−1869
- Kaliberov S.A., Buchsbaum D.J., Gillespie G.Y. et al. Adenovirus-mediated transfer of BAX driven by the vascular endothelial growth factor promoter induces apoptosis in lung cancer cells // Mol. Ther. 2002.- V.6(2).-P. 190−198
- Kalkeri G, Khalap N, Garry RF et al. Hepatits C virus protein expression induced apoptosis in HepG2 cells//Virology 2001, 282(1), 26−37
- Kang P.M., Izumo S. Apoptosis and heart failure: A critical review of the literature// Circ. Res.- 2000.-V. 86, — № 11 .-P. 1107−1113
- Kang S. M., Schneider D. ., Lin Z. et al. Fas- ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction //Nature Med. —1997. Vol. 3, N 7. — P. 738−743.
- Kato N, Yoshida H, Kioko Ono-Nita S. et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer//Hepatology 2000, 32(2), 405−412
- Kawaguchi Y., Takebayashi H., Kakizuka A. et al. Expression of Fas-estrogen receptor fusion protein induces cell death in pancreatic cancer cell lines II Cancer Lett. — 1997.— Vol. 116, N 1. P. 53−59.
- Kawanishi M. Epstein-Barr virus induces fragmentation of chromosomal DNA during lytic infection// J. Virol. 67 (12), 7654−7658 (1993)
- Kerr JF, et al: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 26:239, 1972
- Kim H, Lee H, Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cells//J Biol Chem 1998,273(1), 381−385,
- Kim T.-H., Zhao Y., Barber M. J. et al. Bid induced cytochrome c release is mediated by a pathway independent of mitochondrial permeability transition pore and Bax // The journal of biological chemistry. 2000. — Vol. 275. — N. 50. — P. 39 474−39 481
- Kingham P. J., Pocock J. M. Microglial apoptosis induced by chromogranin A is mediated by mitochondrial depolarisation and the permeability transition but not bycytochrome с release // Journal of neurochemistry. 2000. — Vol. 74. — N. 4. — P. 14 521 462
- Kirsch D.G., Doseff A., Chau B. N. et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome с // The journal of biological chemistry. 2001. — Vol.274.-N. 30.-P. 21 155−21 161
- Kluck R.M., Bossy-Wetzel E., Green D.R. et al. The release of cytochrome с from mitochondria: a primary site for Bcl-2 regulation of apoptosis // Science. 1997. — Vol.275.-P. 1132−1136
- Knodell RG et al. Formulation and application of numerical scoring system for assesing histological activity in asymptomatic chronic active hepatitis//Hepatology 1981- 1 (5): 431−435
- Komatsu K., Suzuki S., Ohara S. et al. Expression of Bcl-2 and Bax in human gastric cancer tissue // Nippon Rinsho. 1996. — Vol. 54. — N. 7. — P. 1929−1934
- Kondo S., Shinomura Y., Kanayama S. et al. Over-expression of Bcl-XL gene in human gastric adenomas and carcinomas // Int. J. Cancer. 1996. — Vol. 68. — N. 6. — P. 727−730
- KorbuttG. S., Elliott J. F., Rajotte R. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression//Diabetes. 1997. — Vol. 46, N 2. — P. 317−322.
- Kornblau S.M., Vu H.T., Ruvolo P. et al. Bax and PKCa modulate the prognostic impact of Bcl-2 expression in acute myelogenous leukemia // Clinical cancer research. -2000.-Vol. 6.-P. 1401−1409
- Koyama S., Koike N., Adachi S. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma // J. Cancer research. Clin. Oncol. 2001. — Vol. 127. — N. 1. — P. 20−26
- Koziel MJ. The role of immune responses in the pathogenesis of hepatitis С virus infection//J Viral Hepat 1997−4 Suppl 2:31−41
- Krajewska M., Fenoglio-Preiser C.M., Krajewski S. et al. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach // American journal of pathology. 1996. — Vol. 149. -N. 5. — P. 1449−1457
- Krajewska M., Moss S.F., Krajewski S. et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas // Cancer research. 1996. — Vol. 56.-N. 10.-P. 2422−2427
- Krammer P. H. CD95's deadly mission in the immune system // Nature. 2000. -Vol. 407. — P. 789−795
- Krueger A., Baumann S., Krammer P. H., Kirchhoff S. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis // Molecular and cellular biology. 2001. — Vol. 21. — N. 24. — P. 8247−8254
- Kurabayashi A., Furihata M., Matsumoto M. et al. Expression of Bax and apoptosis-related proteins in human esophageal squamous cell carcinoma including dysplasia // Mol. Pathol. 2001. — Vol. 306. -N. 3. — P. 741−747
- Lam M., Bhat M. B., Nunez G. et al. Regulation of Bcl-XL channel activity by calcium // The journal of biological chemistry. 1998. — Vol. 273. — N. 28. — P. 1 730 717 310
- Lau H. Yu M., FontanaA., Stoeckert C. J., Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice // Science. 1996. — Vol. 273.1. P. 109−112
- Lebedeva I.V., Stein C.A. Antisense Downregulation of the Apoptosis-related Bcl-2 and Bcl-XL proteins: a new approach to cancer therapy// Molecular Biol.- 2000.-V.34.-N.6.-P.875−888/
- Lee S.S., Cho K.J., Hong S.I. et al. Nuclear overexpression of Bcl-2 oncoprotein during the progression of human stomach cancer // J. Korean. Med. Sci. 1998. — Vol. 13.-N. 2.-P. 153−158
- Leithauser RF, Dhein J, Mechtersheimer G et al. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells // Lab. Invest.- 1993.- V. 69. -P. 415−429
- Li X. K., Okuyama Tamura A. et al. Prolonged survival of recipient rats with Fas-ligand-transfected liver allografts by using HVJ-liposome // Transplant. Proc. — 1998. —Vol. 30, N4.
- Liang Y., Nylander K. D., Yan C., Schor N. F. Role of caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by Bcl-2 // Mol. Pharmacol. 2002. — Vol. 61. — P. 142−149
- Lian-Jun Y., Wen-Liang W. Expression of Bcl-2 and Bax proteins in hepatocellular carcinoma tissue // J. Fourth Mil. Med. Univ. 2002. — Vol. 23. — P. 337 340
- Lim M.L., Minamikawa T., Nagley P. The protonophore CCCP induces mitochondrial permeability transition without cytochrome c release in human osteosarcoma cells // FEBS Lett. 2001. — Vol. 503. — N. 1. — P. 69−74
- Lim S.C. Fas-related apoptosis in gastric adenocarcinoma // Oncol. Rep. 2003. -Vol. 10. -N. 1. — P. 57−63
- Lindblom B, Holmlund G. Rapid DNA purification for restriction fragment length polymorphism analysis // Gene Anal. Tech. 1988. — Vol. 5. — N. 5. — P. 97−101.
- Ling Y.-H., Tornos C., Perez-Soler R. Phosphorylation of Bcl-2 is a marker of M fhase events and not a determinant of apoptosis // The journal of biological chemistry. -1998. Vol. 273. — N. 30. — P. 18 984−18 991
- Liu F.-T., Goff L. K., Hao J.-H et al. Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562cell line// Apoptosis.-2004.-V.9.-P.377−384
- Liu Q. and Gazitt Y. Potentiation of dexamethasone-, paclitaxel-, and Ad-p53-induced apoptosis by Bcl-2 antisense oligodeoxynucleotides in drug-resistant multiple myeloma cells // Blood. 2003. — V. 101. — P. 4105−4114
- Liu X.-H., Castelli J. C., Youle R. J. Receptor-mediated uptake of an extracellular Bcl-XL fusion protein inhibits apoptosis // Proc. Natl. Acad. Sci. USA. 1999. — Vol.96. -N. 17. — P. 9563−9567
- Lock R. B. Bcl-2 inhibits a Fas induced conformational change in the Bax N-terminus and Bax mitochondrial translocation // The journal of biological chemistry. -2000. Vol. 275. -N. 23. — P. 17 225−17 228
- Lorenz HM., Herrmann M, Winkler T., et al. Role of apoptosis in autoimmunity//Apoptosis. 2000. -Vol. 5. -P.443−9.
- Lowe S.L., Rubinchik S., Honda T., McDonnell T.J., Dong J.Y., Norris J.S. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in prostate cancer cells //GeneTher.- 2001.- V.8(18).-P.1363−1371
- Lynch DH., Ramsdell F., Alderson MR. Fas and FasL in the homeostatic regulation of immune responses// Immunol Today. -1995. -Vol. 16. -P.569.
- MacFarlane M., Merrison W., Bratton S. B. et al. Proteasome-mediated degradation of Smac during fpoptosis: XIAP promotes Smac ubiquitination in vitro // The journal of biological chemistry. 2002. — Vol. 277. — P. 36 611−36 616
- Marani M., Tenev T., Hancock D. et al. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis // Molecular and cellular biology. 2002. — Vol. 22. — N. 11. — P. 3577−3589
- Markowitz D., GoffS., Bank A. Construction and use of a safe and efficient amphotropic cell line // J. Virol. — 1988. — Vol. 167. P. 400−406.
- Marone M., Scambia G., Mozzetti S. et al. Bcl-2, Bax, Bcl-XL, and Bcl-XS expression in normal and neoplastic ovarian tissues // Clinical cancer research. 1998. -Vol. 4.-P. 517−524
- Martin A. G., Fearnhead H. O. Apocytochrome c blocks caspase-9 activation and Bax-induced apoptosis // The journal of biological chemistry. 2002. — Vol. 277. — P. 50 834−50 841
- Martin S., Toquet C., Oliver L. et al. Expression of Bcl-2, Bax and Bcl-XL in human gliomas: a re-appraisal // J. Neurooncol. 2001. — Vol. 52. — N. 2. — P. 129−139
- Matsuyama S., Schendel S. L., Xie Z. et al. Cytoprotection by Bcl-2 requires the pore-forming a5 and a6 helices // The journal of biological chemistry. 1998. — Vol. 273. -N. 47. — P. 30 995−31 001
- Maurer C.A., Friess H., Buhler S.S. et al. Apoptosis inhibiting factor Bcl-XL might be the crucial member of the Bcl-2 gene family in colorectal cancer // Dig. Dis. Sci. 1998. — Vol. 43. -N. 12. — P. 2641−2648
- McDonnel J., Bechm A., Sarkiss M. et al. Importance of the Bcl-2 family in cell death regulation // Experientia. 1996. — Vol. 52. — P. 1008−1017
- McDonnell T. J., Troncoso P., Brisbay S. M. et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer // Cancer Res. 1992. — Vol. 52. — P. 6940−6944.
- McGinnis K. M., Gnegy M. E., Wang K. K. W. Endogenous Bax translocation in SH-SY5Y human neuroblastoma cells and cerebellar granule neurons undergoing apoptosis // Journal of neurochemistry. 1999. — Vol. 72. — N. 5. — P. 1899−1906
- Mei X W et al. Induction and detection of apoptosis in human periphery blood T-cells. J. Immunological methods 1997- 206: 153 162.
- Meier P., Finch A., Evan G. Apoptosis in development // Nature. 2000. -Vol.407.-P.796−801.
- Meijerink J. P.P., Mensink E. J.B.M., Wang K. et al. Hematopoietic malignancies demonstrate loss-of-iunction mutations of Bax // Blood. 1998. — Vol. 91. — N. 8. — P. 2991−2997
- Mercatane D.R., Bortner C.D., Cidlowski J.A. et al. Modification of alternative splicing of Bcl-X pre-mRNA in prostate and breast cancer cells // The journal of biological chemistry. 2001 — Vol. 276. — P. 16 411−16 417
- Miller S., Simon J., Vesfig J. Interdisciplinary approaches to gene therapy. Berlin-Heidelberg-New York: Springer, 1997.
- Misao J., Hayakawa Y., Ohno M. et al. Expression of Bcl-2 protein an inhibitor of apoptosis and Bax an accelerator of apoptosis in ventricular myocytes of human hearts with myocardial infarction // Circulation. 1996. — Vol. 94. — P. 1506−1512
- Mita E, Hayashi N, Lio S et al. Role of fas ligand in apoptosis induced by hepatits C infection // Biochem. Boiphis. Res. Commun. 1994. — 204. — P. 468−474
- Mochizuki K, Hiramatsu N, Hayashi N et al. Fas antigen expression in in liver tissues of patient with chronic hepatitis B //J. Hepatol.- 1996.-V. 24.- P. 1−7
- Mok C.-L., Gil-Gomez G., Williams O. et al. Bad can act as a key regulator of T cell apoptosis and T cell development // The Journal of Experimental Medicine. 1999. -Vol. 189. -N. 3.-P. 575−586
- Morris M. J., Tong W. P., Cordon-Cardo C. et al. Phase I Trial of BCL-2 Antisense Oligonucleotide (G3139) Administered by Continuous Intravenous Infusion in Patients with Advanced Cancer //Clin. Cancer Res.- 2002. -V. 8(3).- P. 679 683
- Morrow WJ., Nelson L., Watts R, Isenberg DA. Autoimmune rheumatic disease. 2nd.// Oxford: Oxford University Press. 1999.
- Mossman T. Rapid colorimetric assay for cellular growth and cy-totoxicity assays // J. Immunol. Meth. — 1983. — Vol. 65. — P. 55−63.
- Mounier N., Briere J., Gisselbrecht C. et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2—associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) // Blood. 2003. -V.101. — P. 4279−4284
- Mountz J.D., Wu J., Cheng J., Zhou T. Autoimmune disease: A problem of defective apoptosis// Arthritis Rheum. 1994. -Vol. 37. -P. 1415−1420.
- Mountz J D et al. The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clinical immunology and immunopathology 1996- 80: S2-S14.
- Mullauer L., Gruber P., Sebinger D. et al. Mutations in apoptosis genes: a pathogenetic factor for human disease // Mutat Res. 2001. — Vol. 488. — N. 3. — P. 211 231
- Muller HM, Pfaff E, Goeser T. et al. Peripheral blood leukocytes as a possible extrahepatic site for hepatits C replication. J. Gen. Virol., 1993, 74: 669−676)
- Murphy K/M., Ranganathan V., Farnsworth M.L. et al Bcl-2 inhibits Bax translocation from cytosol to mitochondria during drug-induced apoptosis of human tumor cells. //Cell death and Different. 2000. — Vol.7. — P.102−111.
- Muzio M., Salvesen G.S. and Dixit V.M. FLICE induced apoptosis in a cell-free system. Cleavage of caspase zymogens// J. Biol Chem. 1997. — V. 272. — P. 29 522 956.
- Nadal-Ginard B., Kajstura J., Anversa P., Leri A. A matter of life and death: cardiac myocyte apoptosis and regeneration// J, Clin. Invest.- 2003 .-V. 111.- № 10.-P.1457−1459
- Nagata S., Golstein P. The Fas death factor// Science. 1995. -Vol. 267. -P. 1449−56.
- Nagata S., Suda T. Fas and Fas ligand: lpr and gld mutations// Immunol Today. -1995.-Vol. 16.-P.39.
- Nagata S. Apoptosis by death factor // Cell. 1997. — Vol. 88. — P. 355−365.
- Nagata S. Fas ligand- induced apoptosis// Ann. Rev. Genet. 1999. -Vol. 33. — P. 29−55.
- Nakamuro M., Matute-Bello G., Liles W.C. et al. Differential response of human lung epithelial cells to FAS-induced apoptosis // Am. J. Pathol.-2004.-V.164. P.1949−1958
- Narasimhan S. R., Yang L., Gerwin B. I. et al. Resistance of pleural mesothelioma cell lines to apoptosis relation to expression of Bcl-2 and Bax // Am. J. Physiol. Lung Cell Mol. Physiol. 1998. — Vol. 275. -N. 1. — P. L165-L171
- Narita M., Shimizu S., Ito T. et al. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria // Proc. Natl. Acad. Sci. USA. 1998. — Vol. 95. -N. 25. — P. 14 681−14 686
- Nauman U., M. Weller. Retroviral В AX gene transfer fails to sensitise malignant glioma cells to CD95L-induced apoptosis and cancer chemotherapy.// Int. J. Cancer. -1998. -Vol.77. -P.645−648.
- Nechushtan A., Smith C.L., Lamensdorf I. et al. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis // The journal of cell biology 2001. -Vol. 153.-N. 6.-P. 1265−1276
- Nicolson W.D. From bench to clinic with apoptosis-based therapeutic agents // Nature. 2000. — Vol.407. — P.810−816.
- Nishimoto I., Okamoto Т., Gramorella U., Iwatsubo T. Apoptosis in neurodegenerative disease // Adv.Pharmacol. 1997, v.41, p.337−369.
- Nomura M., Shimizu S., Ito T. et al. Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2 // Cancer research. 1999. — Vol. 59. — P. 5542−5548
- NorrisJ.S., HyerM.L., Voelkel-Johnson C. etal. The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer // Curr Gene Ther.- 2001.-V1(1).-P. 123−136
- O’Connell J., Bennett M.W., Nally K. et al. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict // Ann. N. Y. Acad. Sci.-2000. Vol. 910. — P. 178−192
- Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice//Nature 1993 Aug 26−364(6440):806−809
- Ogura E., Senzaki H., Yamamoto D. et al. Prognostic significance of Bcl-2, Bcl-XL/S, Bax and Bak expressions in colorectal carcinomas // Oncol. Rep. 1999. — Vol. 6. -N. 2.-P. 365−369
- Okamoto K., Asahara H., Kobayashi T. et al. Induction of apoptosis in the rheumatoid synovium by Fas ligand gene transfer// Gene Ther. 1998. — Vol. 5, N 3. — P. 331−338.
- Osaki M., Kase S., Kodani I. et al. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis // Gastric cancer. 2001. — Vol. 4. — N. 4. — P. 198−205
- Oto M., Miyake S., and Yuasa Y. Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus // Analytical biochemistry. 1993. — Vol. 213. — P. 19−22
- Ouyang H., Furukawa T., Abe T. et al. The Bax gene, the promoter of apoptosis, is mutated in genetically unstable cancer of the colorectum, stomach, and endometrium // Clinical cancer research. 1998. — Vol. 4. — P. 1071−1074
- Owen-Shaub L. Fas/APO-1: a cell surface protein mediating apoptosis // Cancer Bull. 1994.-Vol. 46. — P.141−145.
- Ozvaran M.K., Cao X. X., Miller S. D. et al. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma //Mol. Cancer Ther. 2004. -V. 3. -P. 545−550
- Pan H. Yin C., Dyke T. Apoptosis and cancer mechanisms // Cancer Surveys.1997.-Vol. 29.- P.305−327.
- Pastorino J.G., Chen S.T., Tafani M. et al. The overexpression of Bax produces cell death upon induction of the mitochondrial permeability transition. // J. Biol. Chem.1998. Vol.273. — P.7770−7775.
- Peiro G., Diebold J., Mayr D. et al. Prognostic relevance of hMLHl, hMSH2, and Bax protein expression in endometrial carcinoma // Mol. Pathol. 2001. — Vol. 14. — N. 8. — P. 777−783
- Pepper C., Bentley P., Hoy T. Regulation of clinical chemore-sistance by bcl-2 and bax oncoproteins in B-cell chronic lym-phocytic leukaemia // Br. J. Haematol. — 1996. —Vol.95. —P. 513−517.
- Perlman H., Sata M., Le Roux A. et al. Bax mediated cell death by the Gax homeoprotein requires mitogen activation but is independent of cell cycle activity // The EMBO journal. 1998. -Vol. 17.-P. 3576−3586
- Petrella G. T., Beylot-Barry M., Joly P. et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas // Blood. 2004. — V. 103(10). -P. 3662 — 3668
- Pezzella F., Turley H., Keizer I. et al. Bcl-2 protein in non-small-cell carcinoma// N. Engl. J. Med. 1993. — Vol. 329. — P. 690−694.
- Pinkoski M. J., Brunner T., Green D. R. et al. Fas and Fas ligand in gut and liver // Gastrointestinal and liver physiology. 2000. — Vol. 278. — N. 3. — P. G354-G366
- Pirccftnac E.C., Nassirpour R., Yang M. Et al. Bax-induction gene therapy of pancreatic cancer// J. Surg. Res. -2002.- V. 106(2).- P.346−51.
- Pollicino T., Terradillos O, Lecoeur H. et al. Pro-apoptotic effect of the hepatitis B virus X gene//Biomed Pharmacoter, 1998, 52 (9), 363−368-
- Poulaki V., Mitsiades N., Romero M. E. and M. Tsokos Fas-mediated Apoptosis in Neuroblastoma Requires Mitochondrial Activation and Is Inhibited by FLICE Inhibitor Protein and bcl-2 // Cancer Res. June 1.- 2001, — V. 61(12).- P. 4864 — 4872
- Proussakova O.V., Rabaya N.A., Moshnikova A.B. et al. Oligomerization of soluble Fas antigen induces its cytotoxicity // The journal of biological chemistry. 2003. — Vol. 278. -N. 38. — P. 36 236−36 241
- Pryde J. G., Walker A., Rossi A. G. et al. Failure of Bax insertion into mitochondria at 15 °C prevents the release of cytochrome c // The journal of biological chemistry. 2000. — Vol. 275. — N. 43. — P. 33 574−33 584
- Rajagopalan S., Somers E. C., Brook R. D. et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity // Blood. 2004.- V. 103. — P. 3677−3683
- Rampino N., Yamamoto H., Ionov Y., Li Y., Sawai H., Reed J.C., Perucho M. Somatic frameshift mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype // Science. 1997. — Vol. 275. — P. 967−969
- Reed J. C. Balancing cell life and death: Bax, apoptosis, and breast cancer // J. Clin. Invest. 1996. — Vol. 97. — N. 11. — P. 2403−2404
- Reed J.C. Apoptosis-based therapies // Nat. Rev. Drug Discov. 2002. — Vol. 1. -N. 2. -P.111−121.
- Reed J.C. Potential functions of Bcl-2 family proteins. // Advances in pharmacology. 1997. -Vol.41. — P. 510−514.
- Rehermann B, Chang K, McHutchison JG. et al Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection//J.Clin.Invest. 1996. 98.1432−1440
- Rieux-Laucat F., et al. Mutations in Fas associated with human Lymphoproliferative syndrome and autoimmunity// Science. -1995. -Vol. 268. -P. 13 471 349.
- Rose LM., Latchman DS., Isenberg DA. Apoptosis in peripheral lymphocytes in systemic lupus erythematosus: a review// British J. Rheumatol. -1997. Vol. 36. -P. 158 163.
- Roya S., Nicholsona D. W. Cross-talk in cell death signaling // The Journal of Experimental Medicine. 2000. — Vol. 192. — N. 8. — P. F21-F26
- Rudin C. M., Otterson G. A., Mauer A. M. et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer// Ann. One.- 2002.- V. 13(4).-P. 539 545
- RudnerlJ., Lepple-Wienhues A., Budachl W. et al. Wild-type, mitochondrial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but do not affect death receptor-induced apoptosis // Journal of Cell Science. 2001. — Vol. 114. — P. 4161−4172
- Ruvolo P.P., Deng X., May W.S. Phosphorylation of Bcl-2 and regulation of apoptosis // Leukemia. 2001. — Vol. 15. -N. 4. — P. 515−522
- Saegusa M., Takano Y., Okayasu I. Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia // J. Cancer research. Clin. Oncol. 1995. — Vol. 121. — N. 6. — P. 357−363
- Saeterdal I., Bjorheim J., Lislerud K. et al. Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer // Proc. Natl. Acad. Sci. USA.-2001. Vol. 98.-N. 23.-P. 13 255−13 260
- Sahara S., Aoto M., Eguchi Y. et al. Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation // Nature. 1999. — Vol. 401. — N. 6749. -P. 168−173
- Sakuragi N., Ohkouchi T., Hareyama H. et al. Bcl-2 expression and prognosis of patients with endometrial carcinoma // Int. J. Cancer. 1998. — Vol. 79. — P. 153−158.
- Salmon M., Gordon C. The role of apoptosis in systemic lupus erythematosus/ZRheumatology. 1999. -Vol. 38. -P.l 177−1183.
- Savill J., Fadok V. Corpse clearance defines the meaning of cell death // Nature. 2000. — Vol. 407. — P.784−788.
- Sawa H., Kobayashi T, Mukai K. et al. Bax overexpression of enhances cytochrome c release from mitochondria and sensitizes gastric cells to chemotherapeutic agent-induced apoptosis.// Intern. J. Oncol. 2000. — Vol.16 — P.745−749.
- Schaich M., Illmer T., Seitz G. et al. The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia // Haematologica. 2001. — Vol. 86. — N. 5. — P. 470−477
- Schelwies K., Sturm I., Grabowski P. et al. Analysis of p53/Bax in primary colorectal carcinoma: low Bax protein expression is a negative prognostic factor in UICC stage III tumors // Int. J. Cancer. 2002. — Vol. 99. -N. 4. — P. 589−596
- Schendel S. L., Xie Z., Montal M. O. et al. Channel formation by antiapoptotic protein Bcl-2 // Proc. Natl. Acad. Sci. USA. 1997. — Vol. 94. — P. 5113−5118
- Schlesinger P. H., Gross A., X.-M. Yin et al. Comparison of the ion channel characteristics of proapoptotic Bax and antiapoptotic Bcl-2 // Proc. Natl. Acad. Sci. USA. 1997.-Vol. 94.-P. 11 357−11 362
- Schmollinger J. C., Dranoff G. Targeting melanoma inhibitor of apoptosis protein with cancer immunotherapy// Apoptosis.-2004.-V.9.-P.309−314
- Schon M. P., Schon M. Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod// Apoptosis.-2004.-V.9.-P.291−298
- Schwandner O., Schiedeck T.H., Bruch H.P. et al. p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer // Eur. J. Cancer. 2000. — Vol. 36. -N. 3.-P. 348−356
- Sharma S., Saltz L. B. Oral chemotherapeutic agents for colorectal cancer // The Oncologist. 2000. — Vol. 5. -N. 2. — P. 99−107
- Shaw-Stiffel T.A. Chronic hepatitis //Principles and practice of infectious diseases/Mandell, 5th ed" 2000.-P.1298−1320
- Sheehan K.M., O’Donovan D.G., Fitzmaurice G. Prognostic relevance of Fas (Apo-l/CD95) ligand in human colorectal cancer // Eur. J. Gastroenterol. Hepatol. -2003. Vol. 15. — N. 4. — P. 375−380
- Shi Y. Caspase Activation: revisiting the induced proximity model // Cell.- 2004.-V.l 17.-P.855−858
- Shibasaki T., Kondo E., Akagi T., McKeon F. Suppression of signalling through transcription factor NF-AT by interaction between calcineurin and Bcl-2 // Nature. -1997.-Vol. 386.-P. 728−731
- Shigekazu N. Apoptosis by death factor. Cell 1997- 88: 355−365.
- Shilkaitis A., Graves J., Mehta R. R. et al. Bcl-2 and Bax are differentially expressed in hyperplastic premalignant and malignant lesions of mammary carcinogenesis // Cell Growth Differ. 2000. — Vol. 11. — P. 437−445
- Shimoyama M., Kanda T., Liu L. et al. Expression of Fas ligand is an early event in colorectal carcinogenesis // J. Surg. Oncol. 2001. — Vol. 76. — N. 1. — P. 63−68
- Shinoura N., Saito K., Yoshida Y. et al. Adenovirus-mediated transfer of Bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas.//Cancer Gene Ther. 2000. — Vol.7. — P.739−748.
- Shinoura N., Yoshida Y., SadataA. et al. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy // Hum. Gene Ther. —1998. Vol. 9, N 14. — P. 1983−1993.
- Shugar D. Perspectives in antisense Therapeutics // Pharmacol. Ther., 1997, v.76, p.151−160.
- Siegel RM.,. Frederiksen J K., Zacharias D A., et al. Fas pre-association required for apoptosis signaling and dominant inhibition by pathogenic mutations//Science. -2000. -Vol. 288. -P.2354−2357.
- Silvestrini R., Veneroni S., Daidone M. G. et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients // J. Natl. Cancer Inst. 1994. — Vol. 86. — P. 499−504.
- Simonian P.L., Grillot D.A.M., Andrews D.W. et al. Bax homodimerization is not required for Bax to accelerate chemotherapy-induced cell death // The journal of biological chemistry. 1996. — Vol. 271. -N. 50. — P. 32 073−32 077
- Simonian P.L., Grillot D.A.M., Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death // Blood. 1997. — Vol. 90. — N. 3. — P. 12 081 216
- Sinkovics J. G., Horvath J. Can virus therapy of human cancer be improved by apoptosis induction? // Med. Hypothes. —1995. Vol. 44, N 5. — P. 359−368.
- Smith A.E. Gene therapy where are we // The Lancet. — 1999. — V.354. (Suppl. 1). — P.1−4
- Socie G., Mary J -Y., Lemann M. Et al. Prognostic value of apoptotic cells and infiltrating neutrophils in graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas expression // Blood. 2004. — V. 10. — P. 50−57
- Soini Y., Kinnula V., Kaarteenaho-Wiik R. et al. Apoptosis and expression of apoptosis regulating proteins Bcl-2, Mcl-1, Bcl-X and Bax in malignant mesothelioma // Clinical cancer research. 1999. — Vol. 5. — P. 3508−3515
- Song E., Chen J., Ouyang N. et al. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer // Br. J. Cancer. 2001. — Vol. 85. — N. 7. — P. 1047−1054
- Srinivas G., Kusumakumary P., Krishnan M. et al. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leulaemia // J. Cancer research. Clin. Oncol. 2000. — Vol. 126. — P. 62−67
- Steinberg AD., Krieg AM., Gourley MF., Klinman DM. Theoretical and experimental approaches to generalized autoimmunity// Immunol Rev. 1990. -Vol.118. -P. 129−163.
- Steinberg AD., Gourley MF., Klinman DM., et al. Systemic lupus erythematosus// Ann Intern Med. 1991. -Vol. 115. -P.548−559.
- Stoll-Becker S, Repp R, Glebe D et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients//J. Virol 1997, 71 (7), 5399−407
- Strack P.R. Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2 // Proc. Natl. Acad. Sei. USA, 1996, v. 93, p. 9571−9576
- Su F., Schneider R.J. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha//Proc Natl Acad Sei 1997, 94(16), 8744−8749
- Swenson K. M., Ke ., Wang T. et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival // Trans plantation. 1998. — Vol. 65, N 2. — P. 155−160.
- Szymkowski D.E., Developing antisense oligonucleotides from the laboratory to clinical trials. // Drug Discovery Today. 1996. — V.l. — N. 10. — P.415−428
- Takahashi ., Tanaka M., Ogasawara J. et al. Swapping between Fas andgranulocyte colony-stimulating factor receptor // J. Biol. Chem. 1996. — Vol. 271, N 29. — P. 17 555−17 560.
- Takebayashi H., Oida H., Fujisav/a K. et al. Hormone-induced apoptosis by Fas-nuclear receptor fusion proteins: novel biological tools for controlling apoptosis in vivo // Cancer Res. —1996. Vol. 56, N 18. — P. 4164−4170.
- Tanaka M., Suda T., Takahashi T., Nagata S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes// EMBO. 1995. -Vol.14. -P.l 1 291 135.
- Tanaka M., Suda T., Haze K., et al. Fas ligand in human serum// Nat Med. -1996. -Vol. 2. -P.317.
- Terradillos O, Pollicino T, Lecoeur H. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro//Oncogene 1998, 17(16). 2115−2123
- Tokano Y., Miyake S., Kayagaki., N et al. Soluble Fas molecule in serum of patients with systemic lupus erythematosus// J Clin immunol. -1996. -Vol.16. -P.261−265.
- Toshio Miyawaki et al. Differential expression of apoptosis-related Fas Antigen on lymphocyte subpopulations in human peripheral blood. J. Immunology 1992- 149: 3752−3758
- Trent RJ. Molecular medicine // 1997. P.154−173
- Tron V. A., Krajewski S., Klein-Parker H. et al. Immunohisto-chemical analysis of Bcl-2 protein regulation in cutaneous melanoma // Am. J. Pathol. 1995. — Vol. 146. -P. 643−650.
- Tsuruta Y., Mandai M., Konishi I., et. Al Combination effect of adenovirus-mediated proapoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. //European J. Cancer. 2001. — Vol.37. — P.531−541.
- Ulvik A., Aarskog N.K., Ogreid D. Detection and identification of Ki-ras exon 1 mutations by minigel single-strand conformation polymorphism // Analytical biochemistry. 1995. — Vol. 232. — P. 137−138
- Van Lopik Т., Bijl M., Hart M., et al. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse// J Rheumatol. 1999. -Vol.26. -P.60−67.
- Vaux D.L., Strasser A. The molecular biology of apoptosis // Proc. Natl. Acad. Sci. 1996, v.93, p.2239−2244.
- Viruses & Apoptosis By C. L. Alonso, C. Alonso Hardcover / March 2004
- Wagenaar-Miller R.A., Gorden L., Matrisian L.M. Matrix metalloproteinases in colorectal cancer: Is it worth talking about?// Cancer and metastases reviews.-2004.-V.23.-P. 119−135
- Walers C. Molecular mechanism of neuronal cell death // Neurotransmissions. -1997.-Vol. XIII, — P. 1−7.
- Wallach D. Placing death under control // Nature, 1997, v.388, p.123−126.
- Wang X. The expanding role of mitochondria in apoptosis // Genes Dev. 2001. -Vol. 15. — N. 22. — P. 2922−2933
- Wang Z.H., Ding M.X., Chew S.B. et al. Bcl-2 and Bax proteins are nuclear matrix associated proteins.// Anticancer Res 1999. — Vol.19. — P.5445−5450.
- Waters J.S., Webb A., Cunningham D. et al. Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin's Lymphoma// J. Clinical Oncology.-2000.-V. 18.-P. 1812−1823
- Webb A., Cunningham D., Cotter F et al. Bcl-2 antisense therapy in patient with non-Hodgkin lymphoma//Lancet. -1997.- V.349.-P.1137−1141.
- Webster K.A. and Bishopric N. H. Apoptosis Inhibitors for Heart Disease //Circulation. 2003. — V. 108. — P. 2954−2956
- Weller M., Malipiero U., Rensing-Ehl A. et al. Fas/APO-1 gene transfer for human malignant glioma//Cancer Res. — 1995, — Vol. 55, N 13. P. 2936−2944.
- Werner A.B., Vries E., Tait S.W.G. et al. Bcl-2 family member Bfl-l/Al sequesters truncated Bid to inhibit its collaboration with pro-apoptotic Bak or Bax // The journal of biological chemistry. 2002. — Vol. 277. — P. 22 781−22 788
- White E. Regulation of apoptosis by transforming genes of the DNA tumor virus adenovirus//Proc. Soc. Exp. Biol. Med. 1993, 204(1), 30−39)
- Wohlfart S., Sebinger D., Gruber P. et al. FAS (CD95) mutation are rare in gastric MALT Lymphoma but occur more frequently in primary gastric diffuse large B-cell Lymphoma//Am. J. Pathol.-2004.-V.164. P.1081−1089
- Wolf H.K., Stober C., Hohenfellner R. et al. Prognostic value of p53, p21/WAFl, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pTl G3 urothelial bladder carcinomas // Tumour Biol. 2001. — Vol. 22. — N. 5. — P. 328−336
- Woodruff Emlen et al. accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J. immunol. 1994- 152: 3685−3692.
- Wu M.-S., Lee C.-W., Shun C.-T. et al. Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer // Cancer research. 1998. — Vol. 58. — P. 1494−1 497 358. www.genta.com
- Wyllie A.N., Kerr J.F., Currie A.R. Cell death: the significance of apoptosis//Intern. Rev.Cytol.-1980.- V.68. P.251
- Xiang H., Kinoshita Y., Knudson C. M. et al. Bax involvement in p53 mediated neuronal cell death // The journal of neuroscience. 1998. — Vol. 18. — N. 4. — P. 13 631 373
- Xiang J., Chao D.T., Korsmeyer S.J. Bax-induced cell death may not require interleukin 1 p-converting enzyme-like proteases. // Proc. Natl. Acad. Sci. USA. 1996. — Vol.93. — P.14 559−14 563.
- Xiang J., Gomez-Navarro J., Arafat W. et al. Pro-apoptotic treatment with an adenovirus encoding Bax enchances the effect of chemotherapy in ovarian cancer.// J. Gene Medicine. 2000. — Vol.2. — P.97−106.
- Xiang J., Piche A., Rancourt C., et al. An inducible recombinant adenoviral vector ancoding Bax selectively induces apoptosis in ovarian cancer cells. // Tumor targeting. -1999.-Vol. 4.-P. 84−91.
- Xiong H.Q., Ajani J.A. Treatment of colorectal cancer metastasis: The role of chemotherapy // Cancer and metastases reviews.-2004.-V.23.-P. 145−163
- Yagi O.K., Akiyama Y., Nomizu T., Iwama T., Endo M., and Yuasa Y. Proapoptotic gene Bax is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas// Gastroenterology. 1998. — Vol. 114. — P. 268−274
- Yamaguchi H., Wang H.-G. Bcl-XL protects BimEL-induced Bax conformational change and cytochrome c release independent of interacting with Bax or BimEL // The journal of biological chemistry. 2002. — Vol. 277. — P. 41 604−41 612
- Yamamoto H., Sawai H., Weber T.K. et al. Somatic frameshift mutations in DNA mismatch repair and proapoptotic genes in hereditary nonpolyposis colorectal cancer // Cancer research. 1998. — Vol. 58. — P. 997−1003
- Yamamoto K., Ichijo H., Korsmeyer S. J. Bcl-2 is phosphorylated and inactivated by an ASKl/Jun N-terminal protein kinase pathway normally activated at G2/M // Molecular and cellular Biology. 1999. — Vol. 19. — N. 12. — P. 8469−8478
- Yang H.B., Chow N.H., Sheu B.S. et al. The role of Bcl-2 in the progression of the colorectal adenoma-carcinoma sequence // Anticancer Res. 1999. — Vol. 19. — N. IB.-P. 727−730
- Yang J., Liu X., Bhalla K. Et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked // Science. 1997. — Vol. 275. — P. 1129−1132
- Yao M., Cowie A., Wasfy G.W. et al. EBV in latent infection // EMBO J. -1985.-V.15.-P.4130−4141
- Yokota J. Tumor progression and metastasis // Carcinogenesis. 2000. — Vol. 21. -N.3.-P. 497−503
- Zeuner A., Pedini F., Signore M. et al. Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins // Blood. 2003. -V.102. — P. 87−93.
- Zha J., Harada H., Yang E., Joket J., Korsmeyer S.J. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14−3-3 not Bcl-XL // Cell. 1996. — Vol. 87. — P. 619−628
- Zhang H., Xu Q., Krajewski S. et al. Bar: An apoptosis regulator at the intersection of caspases and Bcl-2 family proteins // Proc. Natl. Acad. Sci. USA. 2000. — Vol. 97. — P. 2597−2602
- Zhang H., Yang Y., Horton J. L. et al. Amelioration of collagen-induced arthritis by CD95 (Apo-1 /Fas)-ligand gene transfer // J. Clin. Invest. 1997. — Vol. 100, N 8. — P. 1951−1957.
- Zhao W-L., Daneshpouy M. E., Moimier N. Et al. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma // Blood. 2004. -V. 103.-P. 695−697
- Zhu N., Khoshnan A, Schneider R. et al. Hepatitis C virus core protein binds to the cytoplasmic domain of TNF receptor 1 and enhances TNF-induced apoptosis// J.Virol. 1998, 72(5), 3691−3697
- Zignego AL, Masshia D, Monti M. et al. Infection of peripheral mononuclear blood cells by hepatitis C. J.Hepatol., 1992,15: 382- 386
- Zucker S., Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer // Cancer and metastases reviews.-2004.-V.23.-P. 101−117